MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-10-2023
Syneos Health Book Value 2011-2026 | SYNH
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Syneos Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.41 B | 3.24 B | 3.03 B | 2.86 B | 3.02 B | 301 M | 217 M | 392 M | 276 M | 317 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.41 B | 217 M | 1.71 B |
Quarterly Book Value Syneos Health
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.45 B | 3.5 B | - | - | 3.3 B | 3.41 B | 3.32 B | 3.24 B | 3.24 B | 3.24 B | 3.24 B | 3.24 B | 3.24 B | 3.03 B | 3.03 B | 3.03 B | 3.03 B | 2.86 B | 2.86 B | 2.86 B | 2.86 B | 3.02 B | 3.02 B | 3.02 B | 3.02 B | 301 M | 301 M | 301 M | 301 M | 217 M | 217 M | 217 M | 217 M | 392 M | 392 M | 392 M | 392 M | 276 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.5 B | 217 M | 2.11 B |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
5.39 B | $ 114.25 | -1.07 % | $ 34.7 B |  USA |
 |
Anixa Biosciences
ANIX
|
14 M | $ 2.64 | 3.53 % | $ 85.7 K | USA |
|
Biodesix
BDSX
|
20.9 M | $ 15.55 | 3.19 % | $ 2.02 B | USA |
 |
Biomerica
BMRA
|
4.1 M | $ 2.17 | - | $ 4.98 M | USA |
 |
BioNano Genomics
BNGO
|
44.4 M | $ 1.2 | -0.03 % | $ 6.53 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 16.5 | 1.85 % | $ 178 M |  China |
 |
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
CareDx, Inc
CDNA
|
303 M | $ 18.32 | 0.05 % | $ 976 M | USA |
 |
Celcuity
CELC
|
101 M | $ 113.8 | 1.04 % | $ 5.32 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
20.6 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Charles River Laboratories International
CRL
|
3.21 B | $ 168.44 | -3.13 % | $ 8.35 B | USA |
 |
Castle Biosciences
CSTL
|
456 M | $ 24.85 | 0.04 % | $ 690 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M |  Britain |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 197.89 | 0.37 % | $ 22 B | USA |
 |
Danaher Corporation
DHR
|
83.5 B | $ 190.62 | -0.26 % | $ 136 B | USA |
 |
DexCom
DXCM
|
2.75 B | $ 62.7 | 0.76 % | $ 24.5 B | USA |
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 16.8 | -0.15 % | $ 508 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Guardant Health
GH
|
-99.3 M | $ 92.35 | -1.58 % | $ 11.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | China |
 |
ICON Public Limited Company
ICLR
|
9.52 B | $ 110.38 | -3.34 % | $ 9.1 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
22.4 M | $ 1.96 | 5.82 % | $ 8.67 M | USA |
 |
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | USA |
 |
Illumina
ILMN
|
6.3 B | $ 127.63 | 0.2 % | $ 20.3 B | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | USA |
 |
IQVIA Holdings
IQV
|
6.63 B | $ 168.24 | -2.9 % | $ 28.9 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 274.94 | 0.41 % | $ 22.9 B | USA |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
Lantheus Holdings
LNTH
|
1.09 B | $ 76.0 | -0.14 % | $ 5.13 B | USA |
 |
Medpace Holdings
MEDP
|
459 M | $ 485.89 | -2.5 % | $ 14 B | USA |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 258.2 | -0.3 % | $ 25.9 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
368 M | $ 4.84 | 1.79 % | $ 448 M | USA |
 |
ENDRA Life Sciences
NDRA
|
2.26 M | $ 4.69 | - | $ 3.69 M | USA |
 |
NeoGenomics
NEO
|
837 M | $ 8.06 | 0.75 % | $ 1.03 B | USA |
 |
Neogen Corporation
NEOG
|
2.07 B | $ 9.42 | 0.11 % | $ 2.04 B | USA |
 |
National Research Corporation
NRC
|
14 M | $ 17.35 | 1.11 % | $ 388 M | USA |
 |
Natera
NTRA
|
706 M | $ 207.01 | -0.46 % | $ 20.4 B | USA |
 |
Pacific Biosciences of California
PACB
|
5.35 M | $ 1.36 | 1.49 % | $ 408 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
11 B | $ 27.09 | -0.07 % | $ 20 B |  Niderland |
 |
Precipio
PRPO
|
14.6 M | $ 25.23 | -1.29 % | $ 40.5 M | USA |
 |
Personalis
PSNL
|
203 M | $ 6.63 | 0.76 % | $ 393 M | USA |
 |
RadNet
RDNT
|
1.36 B | $ 55.12 | 0.6 % | $ 4.14 B | USA |